|Rapid review complete
|For the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.